Category : Hamsyl®

Experience with Generic Pegylated L-asparaginase in Children with Acute Lymphoblastic Leukemia from a Tertiary Care Oncology Center in South India

• admin
• November 4, 2024

South Asian J Cancer, 2023 Apr 10;12(4):371-377. doi: 10.1055/s-0042-1759785 https://pubmed.ncbi.nlm.nih.gov/38130281/

Systematic clinical and pharmacological monitoring of a PEG-asparaginase biogeneric (HAMSYL®) in paediatric patients with newly-diagnosed acute lymphoblastic leukaemia

• admin
• November 4, 2024

Pediatr Hematol Oncol. 2023; 8(4):S48. doi: 10.1016/j.phoj.2023.10.122 https://www.sciencedirect.com/science/article/pii/S2468124523001821?via%3Dihub

Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia

• admin
• July 20, 2020

JCO Glob Oncol. 2020 Jul;6:1009-1016. doi: 10.1200/GO.20.00113. https://pubmed.ncbi.nlm.nih.gov/32628582/

Retrospective post-marketing study on the use of bio-similar pegasparagase among acute lymphoblastic leukemia patients in India

• admin
• April 9, 2020

Pediatric Hematology Oncology Journal, Volume 3, Issue 1, March 2018, Pages 9-12 https://www.sciencedirect.com/science/article/pii/S2468124517301031

Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity.

• admin
• April 9, 2020

Pediatr Hematol Oncol. 2018 Aug – Sep;35(5-6):331-340. doi: 10.1080/08880018.2018.1538277 https://www.ncbi.nlm.nih.gov/pubmed/30488741